Does Medicaid cover GLP-1 for weight loss? By state (2026)
Medicaid covers GLP-1s for diabetes almost everywhere. Coverage for weight loss is the variable, state-by-state question — and in 2026 some states cut it. Find yours.
Verified June 2026How Medicaid GLP-1 coverage actually works
Federal rules require state Medicaid programs to cover most FDA-approved outpatient drugs for their approved uses — which is why a GLP-1 prescribed for type 2 diabetes (Ozempic, Mounjaro) is covered nearly everywhere, typically behind prior authorization. Weight-loss drugs are different: states may choose whether to cover the anti-obesity indication, so coverage of Wegovy, Zepbound, or the Foundayo pill for weight loss depends entirely on your state's decision. Even in covering states, expect prior authorization with clinical criteria — a qualifying BMI, documented comorbidities, and sometimes step therapy or a documented lifestyle program. Your day-to-day coverage runs through your managed-care plan's formulary, which follows state policy but is worth confirming directly.
What changed in 2026
Cost pressure hit state budgets, and the map moved in both directions. As of June 2026, 3 states — California, Michigan, Pennsylvania — eliminated weight-loss GLP-1 coverage effective January 2026 (diabetes coverage generally continues), while 13 states are confirmed as still covering at least one GLP-1 for weight loss. States we can't confirm with a cited source are marked "verify" above rather than guessed — that's the standard described in our methodology.
If your state doesn't cover it (or just cut it)
- Confirm the denial reason in writing — "not covered for weight loss" and "prior authorization criteria not met" are very different problems, and the second is often beatable on appeal, including through a state fair hearing.
- Check the strongest indication. If you have type 2 diabetes or qualifying cardiovascular disease, a GLP-1 may be coverable under that indication instead — ask your clinician.
- Dual-eligible? If you also have Medicare Part D, the new Medicare GLP-1 Bridge offers eligible drugs at a flat $50/mo starting July 1, 2026.
- Work the cash ladder. Manufacturer self-pay programs now start around $149/mo for the oral options — the cost page ranks every legitimate path with its catch.
Frequently asked questions
Almost everywhere, yes — Medicaid coverage of GLP-1s for their diabetes indication is near-universal, usually with prior authorization. The hard, state-by-state question this page maps is coverage for weight loss, because drugs like Wegovy, Zepbound, and Foundayo are approved for weight management, not diabetes — see the drug comparison for which is which.
Yes. You can appeal through your managed-care plan, and Medicaid also gives you the right to a state fair hearing. Ask for the denial and the criteria in writing, then follow the appeal playbook — it includes a letter-of-medical-necessity template for your clinician.
If you have Medicare Part D drug coverage, the Medicare GLP-1 Bridge (from July 1, 2026) can get you an eligible GLP-1 for a flat $50/mo — but note the $50 copay is not reduced by Extra Help/LIS and only three products qualify. It can matter most in states that cut Medicaid weight-loss coverage.
Two places: your state Medicaid agency (find it via Medicaid.gov ↗) and your managed-care plan's member line. Ask specifically about "GLP-1 for obesity / weight management," the prior-authorization criteria, and the covered drug list — the diabetes answer and the weight-loss answer are usually different.